CD178 (Fas Ligand) Monoclonal Antibody (MFL3), PE, eBioscience™, Invitrogen™

Description

Description: The MFL3 monoclonal antibody reacts with mouse Fas (CD95) Ligand, a 40 kDa type II transmembrane glycoprotein. FasL is a member of the TNF family and is expressed by mouse activated T cells. The interaction of FasL with its receptor CD95 induces Fas-mediated killing. It has been reported that the human FasL antigen is cleaved from the surface by matrix metalloproteinases (MMPs), resulting in a 26 kDa soluble form. The degree of sensitivity for the mouse antigen to MMPs has not been reported. Applications Reported: The MFL3 antibody has been reported for use in flow cytometric analysis. Applications Tested: The MFL3 antibody has been tested by flow cytometric analysis of mouse FasL transfected cells and activated T cells. This can be used at less than or equal to 1 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 μm post-manufacturing filtered.

Fas ligand (FasL, CD95L) is a type-II-membrane protein, whose N-terminus is in the cytoplasm and its C-terminal region extends into the extracellular space. Its receptor Fas (CD95, Apo-1) is a cell-surface-type-I-membrane protein and a member of the tumor necrosis factor (TNF) and nerve growth factor (NGF) receptor family. As a member of the TNF-cytokine family FasL induces apoptosis when interacting with its receptor Fas. FasL may exist as either membrane bound (45 kD) or soluble forms (26 kD). The soluble protein can be released from cells upon cleavage by metalloproteinases. Binding of FasL to Fas leads to oligomerization of the receptor and triggers apoptotic cell death through the interaction of other proteins. FasL is predomitly expressed in activated T-lymphocytes and natural killer (NK) cells also it is expressed in the tissues of immune-privilege sites such as testis and eye. FasL expression is also reported in various tissues as thymus, liver, ovary, lung, heart and kidney. The Fas/FasL system has been shown to play a role in a number of human diseases, for example AIDS, hepatitis or cancer. It is assumed that induction of apoptosis through FasL is predomitly involved in anti-viral immune responses.